Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 401–500 of 1,000
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
Ma, H., Huang, B., & Zhang, Y. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.004 · Cited by 43
Das, B., Vedachalam, S., Luo, D., Antonio, T., Reith, M. E. A., & Dutta, A. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01031 · Cited by 43
Systems biology impact on antiepileptic drug discovery
Margineanu, D. G. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.10.006 · Cited by 46
Characterization of the dynamic events of GPCRs by automated computational simulations
Gutiérrez‐de‐Terán, H., Bello, X., & Rodriguez, D. J. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120287 · Cited by 42
Devroye, C., Cathala, A., Piazza, P. V., & Spampinato, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.014 · Cited by 43
Jaiteh, M., Rodríguez‐Espigares, I., Selent, J., & Carlsson, J. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007680 · Cited by 47
Kaczor, A. A., Targowska‐Duda, K. M., Budzyńska, B., Biała, G., Silva, A., & Castro, M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.03.003 · Cited by 43
Homayoun, H., & Moghaddam, B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.016 · Cited by 43
Schulz, S., Heidmann, K. E., Mike, Á., Klaft, Z., Heinemann, U., & Gerevich, Z. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02107.x · Cited by 43
Heifetz, A., Schertler, G. F. X., Seifert, R., Tate, C. G., Sexton, P. M., Gurevich, V. V., Fourmy, D., Cherezov, V., Marshall, F. H., Storer, R. I., et al. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1111-8 · Cited by 41
Bianchi, M. T., & Botzolakis, E. J. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-3 · Cited by 43
Role of the cholinergic system in the pathology and treatment of schizophrenia
Scarr, E., & Dean, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.73 · Cited by 45
Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology
McCarroll, M. N., Gendelev, L., Keiser, M. J., & Kokel, D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00800 · Cited by 44
Predictive in silico Off-Target Profiling in Drug Discovery
Schmidt, F., Matter, H., Heßler, G., & Czich, A. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.202 · Cited by 42
Olanzapine: Palliative Medicine Update
Prommer, E. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909112441241 · Cited by 44
Neuropharmacology beyond reductionism – A likely prospect
Margineanu, D. G. (2015) · Biosystems · doi:10.1016/j.biosystems.2015.11.010 · Cited by 45
Todorović, N., & Filipović, D. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.10.006 · Cited by 42
Orphan G protein-coupled receptors: the ongoing search for a home
Jobe, A., & Vijayan, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349097 · Cited by 44
Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands
Ortega, R., Raviña, E., Masaguer, C. F., Areias, F. M., Brea, J. M., Loza, M. I., López, L., Selent, J., Pastor, M., & Sanz, F. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.067 · Cited by 40
Luo, Q., Zhao, L., Hu, J., Jin, H., Liu, Z., & Zhang, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171433 · Cited by 45
Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia
Sekiguchi, H., Pavey, G., & Dean, B. (2019) · Schizophrenia · doi:10.1038/s41537-019-0087-7 · Cited by 42
Cid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 43
Kopec, K. K., Flood, D. G., Ga̧sior, M., McKenna, B. A., Zuvich, E., Schreiber, J., Salvino, J. M., Durkin, J. T., Ator, M. A., & Marino, M. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.004 · Cited by 40
van den Buuse, M., Ruimschotel, E., Martin, S., Risbrough, V. B., & Halberstadt, A. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.001 · Cited by 37
A critical assessment of modeling safety-related drug attrition
Muthas, D., Boyer, S. K., & Hasselgren, C. (2013) · MedChemComm · doi:10.1039/c3md00072a · Cited by 39
Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout Mice
Kurita, M., Moreno, J. L., Holloway, T. D., Kozlenkov, A., Mocci, G., García‐Bea, A., Hanks, J. B., Neve, R. L., Nestler, E. J., Russo, S. J., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084582 · Cited by 43
Zanatta, G., Nunes, G. D., BEZERRA, E. M., da COSTA, R. F., Martins, A. M. C., Caetano, E. W. S., Freire, V. N., & Gottfried, C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500111e · Cited by 39
In Silico Target Prediction for Small Molecules
Byrne, R., & Schneider, G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_16 · Cited by 47
The fall and rise of pharmacology – (Re-)defining the discipline?
Winquist, R. J., Mullane, K., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.011 · Cited by 44
Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents
Calarge, C. A., Ivins, S. D., Motyl, K. J., Shibli-Rahhal, A. A., Bliziotes, M. M., & Schlechte, J. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313487548 · Cited by 41
Wang, X. S., Tang, H., Golbraikh, A., & Tropsha, A. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700404c · Cited by 40
Pharmacogenetics of Leptin in Antipsychotic-Associated Weight Gain and Obesity-Related Complications
Lee, A. K., & Bishop, J. R. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.45 · Cited by 44
Kaur, J., Sundar, S., & Singh, N. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq189 · Cited by 39
The evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 46
Newman‐Tancredi, A., Assié, M. B., Martel, J.-C., Cosi, C., Slot, L. A. B., Palmier, C., Rauly‐Lestienne, I., Colpaert, F. C., Vacher, B., & Cussac, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707158 · Cited by 39
Boeckler, F. M., & Gmeiner, P. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.12.001 · Cited by 39
Polypharmacology Shakes Hands with Complex Aetiopathology
Brodie, J., Marzo, V. D., & Guy, G. W. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.010 · Cited by 38
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
Brown, A., Shi, Q., Moore, T. W., Yoon, Y., Prussia, A. J., Maddox, C. B., Liotta, D. C., Shim, H., & Snyder, J. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4002692 · Cited by 38
Connor, R. M. O., Pusceddu, M. M., Dinan, T. G., & Cryan, J. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.006 · Cited by 41
Cross-Pharmacology Analysis of G Protein-Coupled Receptors
Briansó, F., Carrascosa, M. C., Oprea, T. I., & Mestres, J. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796391285 · Cited by 43
Computational Approaches in Drug Discovery and Design
Pathak, R. K., Singh, D. B., Sagar, M., Baunthiyal, M., & Kumar, A. (2020) · Springer eBooks · doi:10.1007/978-981-15-6815-2_1 · Cited by 52
Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis
Michlmayr, D., & Lim, J. K. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00264 · Cited by 41
The chemist as astronaut: Searching for biologically useful space in the chemical universe
Triggle, D. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.015 · Cited by 39
An update of novel screening methods for GPCR in drug discovery
Chen, L., Jin, L., & Zhou, N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.699036 · Cited by 42
Roskoski, R. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104725 · Cited by 40
Avet, C., Mancini, A. D., Breton, B., Gouill, C. L., Hauser, A. S., Normand, C., Kobayashi, H., Gross, F., Hogue, M., Lukasheva, V., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3586569 · Cited by 40
Allen, J. A., Yadav, P. N., Setola, V, Farrell, M., & Roth, B. L. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.35 · Cited by 37
Self-citationNetwork-Based Methods and Their Applications in Drug Discovery
Yu, Z., Wu, Z., Wang, Z., Wang, Y., Zhou, M., Li, W., Liu, G., & Tang, Y. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01613 · Cited by 38
Enhancing the Accuracy of Chemogenomic Models with a Three-Dimensional Binding Site Kernel
Meslamani, J. E., & Rognan, D. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200166t · Cited by 39
Williams, A. A., Ingram, W. M., Levine, S., Resnik, J., Kamel, C. M., Lish, J. R., Elizalde, D. I., Janowski, S. A., Shoker, J., Kozlenkov, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.81 · Cited by 40
Building a drug–target network and its applications
Lee, S., Park, K., & Kim, D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903322234 · Cited by 39
Schuler, J., Hudson, M. L., Schwartz, D. G., & Samudrala, R. (2017) · Molecules · doi:10.3390/molecules22101777 · Cited by 39
Kołodziej, J., & González–Vélez, H. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-16272-6 · Cited by 40
Gannon, R. L., & Millan, M. J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.059 · Cited by 45
Wang, Y., Monzingo, A. F., Hu, S., Schaller, T. H., Robertus, J. D., & Fast, W. L. (2009) · Biochemistry · doi:10.1021/bi9007098 · Cited by 46
Heffernan, G. D., Coghlan, R. D., Manas, E. S., McDevitt, R. E., Li, Y., Mahaney, P. E., Robichaud, A. J., Huselton, C. A., Alfinito, P. D., Bray, J. A., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.09.023 · Cited by 37
Dual dopamine–5-HT releasers: potential treatment agents for cocaine addiction
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.006 · Cited by 38
Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives
Weston–Green, K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.903156 · Cited by 41
Lauria, A., Tutone, M., & Almerico, A. M. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.06.033 · Cited by 40
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 39
CNS Drug Development – Lost in Translation?
Talevi, A., Bellera, C. L., Ianni, M., Gantner, M. E., Bruno‐Blanch, L. E., & Castro (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712802762356 · Cited by 40
Stolerman, I. P., & Price, L. H. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_200815 · Cited by 36
Pogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1233743 · Cited by 36
Self-citationA general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics
Rusinova, R., Koeppe, R. E., & Andersen, O. S. (2015) · The Journal of General Physiology · doi:10.1085/jgp.201511470 · Cited by 35
Towards High-Throughput Chemobehavioural Phenomics in Neuropsychiatric Drug Discovery
Henry, J., & Włodkowic, D. (2019) · Marine Drugs · doi:10.3390/md17060340 · Cited by 36
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 41
Genome-Scale Screening of Drug-Target Associations Relevant to Ki Using a Chemogenomics Approach
Cao, D., Liang, Y., Deng, Z., Hu, Q., He, M., Xu, Q., Zhou, G., Zhang, L., Deng, Z., & Liu, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057680 · Cited by 39
Effects of antipsychotic treatment on cognition in healthy subjects
Veselinović, T., Schorn, H., Vernaleken, I., Hiemke, C., Zernig, G., Gur, R. C., & Gründer, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112466183 · Cited by 42
Aranda, R., Villalba, K., Raviña, E., Masaguer, C. F., Brea, J. M., Areias, F. M., Domínguez, E., Selent, J., López, L., Sanz, F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800602w · Cited by 35
Choi, Y., Jeong, H. J., Liu, Q. F., Oh, S. T., Koo, B.-S., Kim, Y., Chung, I.-W., Kim, Y. S., & Jeon, S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9636-x · Cited by 35
Zebrafish small molecule screens: Taking the phenotypic plunge
Williams, C. H., & Hong, C. C. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.001 · Cited by 41
Dandapani, S., Lan, P., Beeler, A. B., Beischel, S., Abbas, A. I., Roth, B. L., Porco, J. A. J., & Panek, J. S. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo061758p · Cited by 36
Self-citationTranslational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 35
Face selective reduction of the exocyclic double bond in isatin derived spirocyclic lactones
Rana, S., & Natarajan, A. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob27008k · Cited by 34
A fresh look at cortical dopamine D2 receptor expressing neurons
Quintana, C., & Beaulieu, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.001 · Cited by 38
Multi-targeted drug design strategies for the treatment of schizophrenia
Stępnicki, P., Kondej, M., Koszła, O., Żuk, J., & Kaczor, A. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1816962 · Cited by 36
A Review of Antipsychotics and Priapism
Hwang, T. I. S., Shah, T., & Sadeghi‐Nejad, H. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.10.003 · Cited by 37
Lipogenic effects of psychotropic drugs: focus on the SREBP system
Fernø, J., Skrede, S., Vik‐Mo, A. O., Jassim, G., Hellard, S. L., & Steen, V. M. (2010) · Frontiers in bioscience · doi:10.2741/3675 · Cited by 36
Liégeois, J., Deville, M., Dilly, S., Lamy, C., Mangin, F., Résimont, M., & Tarazi, F. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2013419 · Cited by 33
Suzuki, H., Gen, K., & Inoue, Y. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478281 · Cited by 38
Rojczyk, E., Pałasz, A., & Wiaderkiewicz, R. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.04.001 · Cited by 33
Chagnon, Y. C., Bureau, A., Gendron, D., Bouchard, R.-H., Mérette, C., Roy, M., & Maziade, M. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30554 · Cited by 33
Partyka, A., Kurczab, R., Canale, V., Satała, G., Marciniec, K., Pasierb, A., Jastrzębska‐Więsek, M., Pawłowski, M., Wesołowska, A., Bojarski, A. J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.046 · Cited by 33
Multiple Target-Centric Strategy to Tame Inflammation
Kaur, G., & Silakari, O. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0050 · Cited by 33
Geffen, Y., Nudelman, A., Gil‐Ad, I., Rephaeli, A., Huang, M., Savitsky, K., Klapper, L. N., Winkler, I., Meltzer, H. Y., & Weizman, A. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.002 · Cited by 35
Volpato, A. M., Zugno, A. I., & Quevedo, J. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-1052 · Cited by 36
Systematic Investigation of Dual-Target-Directed Ligands
Lembo, V., & Bottegoni, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00838 · Cited by 35
Kenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
Carrieri, A., Pérez‐Nueno, V. I., Lentini, G., & Ritchie, D. W. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990028 · Cited by 32
Effects of antipsychotics on intestinal motility in zebrafish larvae
de Alvarenga, K. A. F., Sacramento, E. K., Rosa, D. V., Souza, B. R., de Rezende, V. B., & Romano‐Silva, M. A. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.13006 · Cited by 32
Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities
Otero, E., García, E., Palacios, G., Yepes, L. M., Cardá, M., Agut, R., Vélez, I. D., Cardona‐Galeano, W., & Robledo, S. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.064 · Cited by 32
Ligand Binding Site Structure Influences the Evolution of Protein Complex Function and Topology
Abrusán, G., & Marsh, J. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.085 · Cited by 36
Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
Harrison, P. T., & Huang, P. H. (2018) · Essays in Biochemistry · doi:10.1042/ebc20180016 · Cited by 34
Exploring the Role of Neurotransmitters in Multiple Sclerosis: An Expanded Review
Akyüz, E., Celik, B. R., Aslan, F. Ş., Sahin, H., & Angelopoulou, E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00589 · Cited by 33
Multitargeted therapy: Can promiscuity be praised in an era of political correctness?
Jimeno, A., & Hidalgo, M. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.005 · Cited by 36
Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs
Bulterijs, S., & Braeckman, B. P. (2020) · Pharmaceuticals · doi:10.3390/ph13080164 · Cited by 33
Sloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Pharmacotherapy for Treatment-Resistant Depression
Vas, C., Jain, A., Trivedi, M., Jha, M. K., & Mathew, S. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.012 · Cited by 32
The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs
Egyed, A., Kiss, D. J., & Keserű, G. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.847788 · Cited by 32
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.